Table 3.

Clinical Characteristics in 9 Patients With Hemodynamics Consistent With Precapillary PH

Precapillary PH or PAH (n=9)
Clinical characteristics
 Age, y68.3 (10.3)
 Men, n (%)4 (44)
 BMI, kg/m229.3±3
 Active smokers, n (%)1 (11)
 NYHA class III or IV, n (%)8 (89)
 Obstructive CAD, n (%)3 (33)
 Hypertension, n (%)2 (22)
 Any PH-related comorbidity, n (%)1 (11)
Medications at RHC, n (%)
 β-blockers8 (89)
 Calcium-channel blockers3 (33)
 Disopyramide0 (0)
 Diuretics3 (33)
Echocardiography
 LVOT gradient at rest, mm Hg70 [60–80]
 Peak LVOT gradient, mm Hg80 [70–110]
 LVEF, %63 [61–72]
 Maximum LV thickness, mm20±4
 MR moderate or severe, n (%)4 (44)
 LA volume index, mL/m246 [41–59]
 RV diameter (mm)43 [33–43]
 RV diameter >42 mm, %56
 RV fractional area change (%)43 [40–46]
Cardiopulmonary hemodynamics
 mPAP, mm Hg28 [27–34]
 TPG, mm Hg18 [14–19]
 PAWP, mm Hg13 [12–14]
 PVR, WU3.44 [3.27–4.75]
 CI, L/m22.07 [1.92–2.37]
 DPG ≥7 mm Hg, %4 (44)
Invasive therapy
 Surgical myectomyn=5
 Alcohol septal ablationn=4
 Major complicationsn=0
 Postoperative NYHA In=7
 Postoperative NYHA IIn=2
  • For normally distributed data, results are reported as mean±SD. For data not distributed normally, results are reported as median (interquartile range). BMI indicates body mass index; CAD, coronary artery disease; CI, cardiac index; DPG, diastolic pressure gradient; LV, left ventricular; EF, ejection fraction; LVOT, left ventricular outflow tract; mPAP, mean pulmonary artery pressure; MR, mitral regurgitation; NYHA, New York Heart Association; PAH, pulmonary arterial hypertension; PAP, pulmonary artery pressure; PASP, pulmonary artery systolic pressure; PAWP, pulmonary artery wedge pressure; PH, pulmonary hypertension; PVR, pulmonary vascular resistance; TPG, transpulmonary gradient; and WU, Wood units.